We further demonstrated that treatment with the demethylation reagent Aza upregulated FBP1 expression in lowly expressed cancer cells (Figure 1B) and the methylation status was verified by genomic sequencing, indicating that DNA hypermethylation mediated FBP1 inactivation. Here, FBP1 is linked to cancer.